Mean pain intensity (Numeric Rating Scale 0–10) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in mean pain intensity (Numeric Rating Scale 0–10) compared with placebo medication (moderate certainty).
1 finding from 1 review
Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · postoperative pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · postoperative pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anthropometric recovery: percentage of children who recover from moderate or severe wasting Defined as % children aged 6–59 months who recovered in treatment programmes for moderate or severe malnutrition (Wroe 2021) · children aged > 6 months and ≤ 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric recovery: improvement from severe wasting Defined as MUAC ≥ 115 mm, clinically well, absence of oedema for 2 consecutive visits, and minimum stay of 8 weeks in the programme (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention may leads to lower anthropometric recovery: improvement from severe wasting Defined as… (low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric recovery Defined as: WHZ ≥ −1.5 or MUAC > 125 mm for 2 consecutive visits and absence of nutritional oedema for 14 days (Alvarez Moran 2018b); absence of oedema and WHZ ≥ −1.5 or MUAC > 125 mm (Charle‐Cuellar 2021c; no oedema and we... · children aged > 6 months and < 5 years with wasting
It is very uncertain whether the intervention changes anthropometric recovery Defined as: WHZ ≥ −1.5 or MUAC > 125 mm for… (very low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: total MUAC gain Defined as MUAC at discharge − MUAC on admission among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: MUAC gain per day Defined as (discharge MUAC − admission MUAC)/days in treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: total weight gain (g/kg) Defined as (weight at discharge − weight on admission)/weight on admission among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: mean weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/admission weight)/days in treatment (Wilunda 2021)e · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: median weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/weight on admission)/days on treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with normal or underweight WHZ on discharge Defined as WHZ > −2 (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with normal or… (low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with WHZ in moderate wasting range on discharge Defined as WHZ between −3 and −2 (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with WHZ in moderate… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with WHZ in severe wasting range on discharge Defined as WHZ < −3: Hussain 2021 · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with WHZ in severe… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with MUAC ≥ 115 mm on discharge (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with MUAC ≥ 115 mm on… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: weight gain per day (g/kg/day) Calculated as ((discharge weight − admission weight)/weight on admission)/days in treatment among recovered children (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
1 finding from 1 review
Bibliometric scores · peer reviewers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraventricular haemorrhage, Papile grade 3/4 · the fetus/neonate/infant
Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroid showed no clear difference in A9: Severe intraventricular haemorrhage (grade 3 or 4) – all fetuses… compared with single course (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review